Only 1.5% of Africa’s population is fully vaccinated against COVID-19, but according to a recent FiercePharma article, that number is about to go up drastically. The U.S. is investing $200 million in an Aspen Pharmacare manufacturing facility in South Africa to boost the production of the Johnson & Johnson vaccine. The funds will allow the plant to increase capacity far beyond its current rate of 300 million doses per year. J&J has gone on record as saying it is providing its vaccine on a “not-for-profit basis” during the global pandemic, and pledged 500 million doses to the COVAX worldwide relief initiative last December.
U.S. Gives $200M to Boost Vaccines in Africa
The investment will increase production capacity of the J&J vaccine beyond its current rate of 300 million doses per year.
Jul 30, 2021
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here